Tau activation of microglial cGAS-IFN reduces MEF2C-mediated cognitive resilience.

Udeochu JC, Amin S, Huang Y, Fan L, Torres ERS, Carling GK, Liu B, McGurran H, Coronas-Samano G, Kauwe G, Mousa GA, Wong MY, Ye P, Nagiri RK, Lo I, Holtzman J, Corona C, Yarahmady A, Gill MT, Raju RM, Mok SA, Gong S, Luo W, Zhao M, Tracy TE, Ratan RR, Tsai LH, Sinha SC, Gan L. · 2023

Read Tau activation of microglial cGAS-IFN reduces MEF2C-mediated cognitive resilience. by Udeochu JC, Amin S, Huang Y, Fan L, Torres ERS, Carling GK, Liu B, McGurran H, Coronas-Samano G, Kauwe G, Mousa GA, Wong MY, Ye P, Nagiri RK, Lo I, Holtzman J, Corona C, Yarahmady A, Gill MT, Raju RM, Mok SA, Gong S, Luo W, Zhao M, Tracy TE, Ratan RR, Tsai LH, Sinha SC, Gan L. (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc10166855.txt.

Introduction

Udeochu and a large team report that tau protein switches on an immune alarm in microglia that weakens the brain's resilience, in a 2023 study. Alzheimer's disease develops for years before symptoms appear. During that silent phase, some brains stay sharp despite building damage, a trait called cognitive resilience.

The team found that tau activates a DNA sensor, cGAS, in microglia, the brain's immune cells. That alarm lowers a protective protein, MEF2C, and resilience falls. The pathway may offer targets to keep minds sharp longer. It also helps explain why resilience varies.

Catalog record

CREATORUdeochu JC, Amin S, Huang Y, Fan L, Torres ERS, Carling GK, Liu B, McGurran H, Coronas-Samano G, Kauwe G, Mousa GA, Wong MY, Ye P, Nagiri RK, Lo I, Holtzman J, Corona C, Yarahmady A, Gill MT, Raju RM, Mok SA, Gong S, Luo W, Zhao M, Tracy TE, Ratan RR, Tsai LH, Sinha SC, Gan L.
YEAR2023
COLLECTIONPAPERS
FORMATTXT
FILE SIZE91 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC10166855

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Tau activation of microglial cGAS–IFN reduces MEF2C-mediated cognitive resilience By Joe C. Udeochu, Sadaf Amin, Yige Huang, Li Fan, Eileen Ruth S. Torres, Gillian K. Carling, Bangyan Liu, Hugo McGurran, Guillermo Coronas-Samano, Grant Kauwe, Gergey Alzaem Mousa, Man Ying Wong Published in: Nature neuroscience DOI: 10.1038/s41593-023-01315-6 ABSTRACT Pathological hallmarks of Alzheimer’s disease (AD) precede clinical symptoms by years, indicating a period of cognitive resilience before the onset of dementia. Here, we report that activation of cyclic GMP–AMP synthase (cGAS) diminishes cognitive resilience by decreasing the neuronal transcriptional network of myocyte enhancer factor 2c (MEF2C) through type I interferon (IFN-I) signaling. Pathogenic tau activates cGAS and IFN-I responses in microglia, in part mediated by cytosolic leakage of mitochondrial DNA. Genetic ablation of Cgas in mice with tauopathy diminished the microglial IFN-I response, preserved synapse integrity and plasticity and protected against cognitive impairment without affecting the pathogenic tau load. cGAS ablation increased, while activation of IFN-I decreased, the neuronal MEF2C expression network linked to cognitive resilience in AD. Pharmacological inhibition of cGAS in mice with tauopathy enhanced the neuronal MEF2C transcriptional network and restored synaptic integrity, plasticity and memory, supporting the therapeutic potential of targeting the cGAS–IFN–MEF2C axis to improve resilience against AD-related pathological insults. Alzheimer’s disease (AD) is the most common late-onset dementia. A long preclinical asymptomatic period with increasing deposition of amyloid-β plaques and tau aggregates transforms to a symptomatic phase with cognitive decline1–3. While the transition is poorly understood, it coincides with alterations in innate immune responses, vasculature and metabolism3. Susceptibility to sporadic late-onset AD is linked to single-nucleotide polymorphisms in innate immune genes4,5, suggesting that maladaptive innate immune responses underlie the cognitive decline. Antiviral response pathways are upregulated in AD and regulate microglial disease responses, including immune activation/suppression and synaptic pruning in aging and neurodegenerative diseases6–9. Cyclic GMP–AMP synthase (cGAS), the major antiviral DNA sensor, binds double-stranded DNA (dsDNA) and catalyzes cyclic GMP–AMP (cGAMP) formation, which activates stimulator of interferon (IFN) genes (STING). STING recruits tank binding kinase 1 (TBK1) and promotes TBK1 autophosphorylation to activate type I IFN (IFN-I) expression10. The cGAS–STING pathway drives deleterious IFN-I activation in neurodegenerative diseases, including Parkinson’s disease, amyotrophic lateral sclerosis and Huntington’s disease11–13. cGAS–STING activation exacerbates amyloid-β pathology in 5xFAD mice14. While tau activates the cGAS–STING pathway and increases NF-κB signaling in cultured microglia15, how cGAS activation renders the brain vulnerable to tau-related cognitive decline remains unknown. Here, we investigated cGAS–STING–IFN activation in microglia in mice with tauopathy and in brain samples from individuals with AD. Using behavior, electrophysiology and single-nuclei RNA sequencing (snRNA-seq), we demonstrated potent protective effects of Cgas genetic deletion against synaptic and cognitive deficits associated with induction of the transcriptional network of myocyte enhancer factor 2c (Mef2c), a gene implicated in cognitive resilience16. snRNA-seq analyses of AD brains revealed dysregulation of microglial IFN-I genes and the neuronal MEF2C transcriptional network. We propose a mechanism of maladaptive innate immune responses that confers cognitive vulnerability and present therapeutic strategies to enhance resilience against AD-related dementia. RESULTS cGAS–STING is activated in tau transgenic mice and human AD To characterize gene expression changes in tauopathy, we performed bulk RNA-seq of P301S tau transgenic and non-transgenic hippocampi (8–9 months; Extended Data Fig. 1a,b). IFN genes were upregulated in P301S transgenic hippocampi compared to in non-transgenic hippocampi, and transcription factor (TF) motifs of IFN response factors (IRFs) and IFN-sensitive response elements (ISREs) were enriched (Fig. 1a–c and Supplementary Table 1). Ingenuity Pathway Analysis (IPA) of predicted regulators of upregulated differentially expressed genes (DEGs) confirmed components of IFN signaling (Ifnar1, Stat1 and Irf3). Components of the cGAS–STING pathway (cGAS, STING and TBK1) were predicted activators of upregulated DEGs (Fig. 1d and Extended Data Fig. 1c). Immunoblotting for TBK1 phosphorylation revealed increased TBK1 phosphorylation in P301S transgenic hippocampal lysates (Fig. 1e,f). By immunofluorescent labeling, we further confirmed that microglial STING expression was increased in P301S transgenic hippocampi compared to in non-transgenic hippocampi (Fig. 1g,h). Activation of cGAS–STING was further analyzed in previously published microarray profiles of hippocampi from 3-, 6-, 9- and 12-month-old P301S transgenic mice17. IRF and ISRE TF motifs were enriched in DEGs associated with tauopathy (Extended Data Fig. 1d,e). Using weighted gene correlation analysis18, we assessed the temporal nature of expression changes in P301S transgenic mice and identified three distinct gene expression modules: blue, midnight blue and lime green (Extended Data Fig. 1f)18. Lime green and midnight blue modules were positively associated with transgene expression (Supplementary Table 2). Notably, lime green (up at all ages) was enriched with terms such as cytoskeleton organization and cell cycle, reflecting early disease (Extended Data Fig. 1g,h)19. Cgas and mitochondrial antiviral signaling protein (Mavs) genes were part of the lime green module, implicating cytosolic nucleic acid-sensing pathways in the induction of innate immune responses of tauopathy (Extended Data Fig. 1i). IFN signaling is upregulated in AD brains6–8. To determine cGAS involvement in that response, we assessed phosphorylated TBK1 (pTBK1) levels in healthy and AD (Braak stage 0 versus 6) postmortem brain samples (Supplementary Table 3). pTBK1 levels were elevated in AD brains (Fig. 1i,j). Thus, the cGAS–STING pathway is activated in P301S transgenic mice with tauopathy and in AD brain samples. Tau induces mitochondrial DNA leakage and IFN activation We next sought to determine if pathogenic tau activates IFN signaling in microglia. Using enzyme-linked immunosorbent assays (ELISAs) and MAGPIX assays, we measured IFNβ, CXCL10 and CCL5 protein expression in culture medium from primary microglia treated with tau fibrils (Fig. 2a). Treatment with fibrils led to robust TBK1 phosphorylation, suggesting activation of cGAS–STING signaling (Fig. 2b,c). Genetic ablation of Cgas in primary microglia abolished tau-mediated cytokine expression (Fig. 2d). The responses of Cgas−/− and Cgas+/+ primary microglia treated with tau fibrils or herring testis DNA (HT-DNA) were compared using RNA-seq. Almost 80% of genes upregulated by tau were upregulated by HT-DNA, and IFN signaling pathways were overrepresented in these shared DEGs (Fig. 2e,f). Consistent with the canonical role of cGAS as a cytoplasmic DNA sensor, microglial transcriptional responses to HT-DNA were abolished in Cgas−/− microglia (Extended Data Fig. 2a,b). Cgas deletion reduced the expression of tau-induced IFN-stimulated genes (Stat1, Ddx60, Isg20, Rnf213, Parp12, Ifi35, Sp100 and others; Fig. 2g) and genes encoding cytokines and inflammatory cytokines (Extended Data Fig. 2c,d). How does tau induce cGAS-mediated IFN activation? In primary microglia treated with tau, electron microscopy and immunogold labeling showed that tau localized to lysosomes and mitochondria (Fig. 2h). Tau fibril treatment also led to mitochondrial DNA (mtDNA) release into the cytosol (Fig. 2i). To quantify IFN responses, we generated an IFNβ–luciferase reporter BV2 cell line, which upregulates IFNβ–luciferase in response to cGAS agonists (cGAMP and HT-DNA) and tau fibrils (Extended Data Fig. 2e,f). We generated mtDNA-depleted cells by treating IFNβ reporter BV2 cells with dideoxycytidine (ddC) or low-dose ethidium bromide (EtBr)20,21. mtDNA was depleted in a dose-dependent manner after ddC and EtBr treatment (Fig. 2j). In control experiments, the BCL-2 inhibitor ABT-737 and caspase inhibitor Q-VD-OPH (QVD), which trigger mtDNA leakage without apoptosis induction22,23, activated IFNβ-dependent luciferase expression that was dampened with ddC- or EtBr-induced mtDNA depletion, confirming activation of IFN-I by cytosolic mtDNA (Extended Data Fig. 2g). After tau treatment, ddC and EtBr dampened the microglial IFNβ response in a dose-dependent manner, implicating mtDNA in tau-dependent

Read the complete text